At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 383 enrolled
Drug / intervention
AZD0585 +1 moredrug
Likely dose
AZD0585 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.
In Brief
A Phase 3 clinical trial evaluating AZD0585 and AZD0585 placebo for Hypertriglyceridemia. Completed, enrolled 383 participants across 26 sites.
Detailed Summary
This study is a randomised, double-blind phase III long-term study to evaluate efficacy and safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients with hyperlipidemia accompanied by hypertriglyceridemia .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertriglyceridemia
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJun 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedJun 4, 2015
Enrollment StartJun 10, 2015
Primary CompletionMar 11, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.1 years ago
Interventions
AZD0585drug
1g soft capsule
AZD0585 placebodrug
1g soft capsule